Back to Browse Journals » ClinicoEconomics and Outcomes Research » Volume 4

Health expenditure comparison of extended-release metoprolol succinate and immediate-release metoprolol tartarate

Authors Vaidya V, Patel P

Published Date February 2012 Volume 2012:4 Pages 49—56

DOI http://dx.doi.org/10.2147/CEOR.S27609

Received 24 October 2011, Accepted 29 November 2011, Published 7 February 2012

Varun Vaidya, Pranav Patel
College of Pharmacy and Pharmaceutical Sciences, University of Toledo, Toledo, OH, USA

Background: Metoprolol, a selective beta-1 blocker, is available in two different salt forms in the market – metoprolol succinate (MS) and metoprolol tartarate (MT). Both the formulations are Food and Drug Administration approved for the treatment of hypertension. Several studies have shown similar efficacies between the two salts; however, they differ in their pharmacokinetic properties and are therefore priced differently. The primary objective of this study was to compare the overall health care expenditures of hypertensive patients on MT and MS to see if the price difference in the two preparations is offset by savings in overall expenditure.
Methods: Two cohorts of patients using MT and MS were selected from the 2008 Medical Expenditure Panel Survey. Propensity score matching technique was used to balance the cohorts on various parameters such as demographic information, insurance status, and comorbidity score. Patients using MT were matched to patients using MS on the logit of propensity score using calipers of width equal to 0.2 of the standard deviation of the logit of the propensity score. Multiple regression analysis was carried out to examine the association between health expenditure and type of metoprolol salt, adjusting for other covariates.
Results: A total of 742 patients were found to use metoprolol (MT-388, MS-354). After propensity score matching, a total of 582 patients were left in the sample for final analysis (291 patients in each cohort). The average annual health care expenditure was slightly higher in the MT cohort; however, after adjusting for covariates in a multivariate analysis, the difference was found to be statistically insignificant (P = 0.23).
Conclusion: Both the products of metoprolol were found to have similar average annual total health care expenditure; however, MS once a day has higher out-of-pocket cost.

Keywords: hypertension, cost, propensity score

Download Article [PDF] View Full Text [HTML] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Other articles by this author:

Utilization of preventive care services and their effect on cardiovascular outcomes in the United States

Varun Vaidya, Gautam Partha, Jennifer Howe

Risk Management and Healthcare Policy 2011, 4:1-7

Published Date: 19 January 2011

Demographic disparities in patient-reported use of inhaled corticosteroids among patients with persistent asthma

Varun Vaidya, Monica Holiday-Goodman, Sharrel Pinto

Journal of Asthma and Allergy 2010, 3:101-106

Published Date: 24 August 2010

Readers of this article also read:

Therapeutic efficiency of folated poly(ethylene glycol)-chitosan-graft-polyethylenimine-Pdcd4 complexes in H-ras12V mice with liver cancer

Kim YK, Minai-Tehrani A, Lee JH, Cho CS, Cho MH, Jiang HL

International Journal of Nanomedicine 2013, 8:1489-1498

Published Date: 16 April 2013

Preparation, characterization and application of star-shaped PCL/PEG micelles for the delivery of doxorubicin in the treatment of colon cancer

Gao X, Wang BL, Wei XW, Rao W, Ai F, Zhao F, Men K, Yang BW, Liu XY, Huang MJ, Gou ML, Qian ZY, Huang N, Wei YQ

International Journal of Nanomedicine 2013, 8:971-982

Published Date: 8 March 2013

A randomized crossover study comparing tafluprost 0.005% with travoprost 0.004% in patients with normal-tension glaucoma

Mizoguchi T, Ozaki M, Unoki K, Dake Y, Eto T, Arai M

Clinical Ophthalmology 2012, 6:1579-1584

Published Date: 25 September 2012

Critical appraisal of the role of davunetide in the treatment of progressive supranuclear palsy

Gold M, Lorenzl S, Stewart AJ, Morimoto BH, Williams DR, Gozes I

Neuropsychiatric Disease and Treatment 2012, 8:85-93

Published Date: 9 February 2012

The effect of intravitreal anti-VEGF agents on peripheral wound healing in a rabbit model

Christoforidis J, Ricketts R, Pratt C, Pierce J, Bean S, Wells M, Zhang X, La Perle K

Clinical Ophthalmology 2012, 6:61-69

Published Date: 10 January 2012

Erratum

Utine CA

Clinical Ophthalmology 2011, 5:1415-1416

Published Date: 28 September 2011

Graft-free Ahmed tube insertion: a modified method at 5 mm from limbus

Juan Carlos Mesa-Gutiérrez, Juan Lillo-Sopena, Anna Monés-Llivina, et al

Clinical Ophthalmology 2010, 4:359-363

Published Date: 20 April 2010

Management of COPD in general practice in Denmark – participating in an educational program substantially improves adherence to guidelines

Charlotte Suppli Ulrik, Ejvind Frausing Hansen, Michael Skov Jensen, et al

International Journal of Chronic Obstructive Pulmonary Disease 2010, 5:73-79

Published Date: 11 March 2010

Diabetes mellitus: a prothrombotic state. Implications for outcomes after coronary revascularization

Clarissa Cola, Salvatore Brugaletta, Victoria Martín Yuste, Bieito Campos, Dominick J Angiolillo, Manel Sabaté

Vascular Health and Risk Management 2009, 5:101-119

Published Date: 11 January 2009

Mechanisms of endothelial dysfunction in obstructive sleep apnea

Amy Atkeson, Sanja Jelic

Vascular Health and Risk Management 2008, 4:1327-1335

Published Date: 7 October 2008